Recursion Pharma Files Proxy Statement, No Fee

TL;DR

Recursion Pharma (RXRX) filed a proxy statement, no fee required. Standard procedure.

AI Summary

Recursion Pharmaceuticals, Inc. filed a DEFA14A proxy statement on September 4, 2024, indicating it is soliciting materials under Rule 14a-12. The filing does not require a fee. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing is a routine procedural step for Recursion Pharmaceuticals, Inc. as they prepare for shareholder engagement or corporate actions requiring proxy solicitation.

Risk Assessment

Risk Level: low — This is a standard SEC filing (DEFA14A) for proxy solicitation, not indicating any immediate financial or operational risks.

Key Players & Entities

• Recursion Pharmaceuticals, Inc. (company) — Registrant
• 0001601830-24-000153 (filing_id) — Accession Number
• 20240904 (date) — Filing Date
• Rule 14a-12 (regulation) — Soliciting Material

FAQ

Key Financial Figures

• $2 b — ing a new drug to market, it takes over $2 billion, 10% likelihood of success. And f
• $30million — th ago where Roche, Genentech paying us $30million for that. Exscientia team doing extraor
• $2 billion — pment process that is characteristic of $2 billion to spend, 10 years of developed – of ti
• $100 million — t of the merger that you expect roughly $100 million in synergies per year moving forward. W
• $200 million — he next 24months of delivering north of $200 million in milestones. So we're not going to do
• $30 million — and Bayer. As I talked before, we had a $30 million payment for how we've been constructing

Filing Documents

• recursion-solicitationmate.htm (DEFA14A) — 82KB
• 0001601830-24-000153.txt ( ) — 83KB

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ____________________________ Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box Preliminary Proxy Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Recursion Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. In connection with the transaction contemplated by the previously announced transaction agreement (the "Transaction Agreement"), dated August 8, 2024, among Recursion Pharmaceuticals, Inc. (the "Company" or "Recursion") and Exscientia plc, a public limited company incorporated under the laws of England and Wales with registered number 13483814 ("Exscientia"), Michael Secora, CFO of Recursion, appeared at the Morgan Stanley Healthcare Conference on September 4, 2024, with David Hallett, interim CEO of Exscientia. Below is a transcript of the discussion. Morgan Stanley Healthcare Conference – Wednesday, September 4, 2024 – Conference Transcript Management Discussion Section Vikram Purohit (Analyst from Morgan Stanley) All right. Welcome, everyone. Let's go ahead and get started. This is the fi reside chat with Exscientia and Recursion. My name is Vikram Purohit. I'm one of the biotech analysts with the Morgan Stanley research team. Really quick disclosure, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.comresearchdisclosures. With that, happy to have with me Dave Hallett from Exscientia, Mike Secora from Recursion. Thanks for joining us. Appreciate it. Dave and Mike, the best place to start maybe might just be the recently announced business combination between the two companies. Would just love to unpack the rationale for that, what you see as the obvious areas of overlap between the technologies and then we can go from there. David Hallett (Exscientia) Sure. Maybe I'll start and then I'll pass over to Mike. The way I think about unpacking that combination is that, on a very high level, you have Recursion who is a very mission driven organization, who are applying technology, generating significant amounts of proprietary data and applying that to decode biology, and that what that really means is to try and kind of glean, unique insights and to identify some root causes of kind of the biology that list the disease. On the flip side, Exscientia, again, on a very high level, has been very much focused on the generation of small molecules against targets. The kind of idea being here that if you look at one of the major reasons why small molecules fail and therefore why it is so expensive to do small molecule drug discovery development is that they were poorly designed and therefore issues were baked into those compounds on the day they were designed. And so we focused very much on how can we use kind of AI and technology and methods to improve the kind of probability of success. And so by bringing the two together, two platforms together, you create a kind of an end to end kind of capability where you've got the kind of unique insights around, say, around novel first-in-class targets and kind of Recursion's pipeline. And then couple that with the ability to then derive truly kind of best in class compounds from that. That's a very, very compelling combination. On top of that, you've got the pipeline. So our two pipelines reflect that kind of our approach so far. So, Recursion, kind of mainly kind of a first-in-class kind of novel biology, kind of, a lot of rare diseases. In the first version of the pipeline, we're very much around best-in-class, larger target space in oncology. And so the tubes actually stitched together very neatly. There's no overlap there. There's orthogonal kind of risk and reward. So it helps to de-risk the kind of two pipelines. And then the partnerships. Partnerships is a very compelling proposition. So, we, Exscientia have a significant combination with Sanofi kind of in the oncology and IA space that's been going a few years now. We have a collaboration with Merck KGaA. Recursion, on the other hand, have two significant collaborations. One with Roche-Genentech, which I'll Michael talked about, and also one with Bayer. And then last, but not least is the people. We have a huge kind of talent base of people sat within North America and in Europe. And post-close, I'm really looking

View Full Filing

View this DEFA14A filing on SEC EDGAR